If you have been reading about GHRH receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-16. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Carisoprodol, sold under the brand name Soma among others, is an oral medication used for musculoskeletal pain. Effects generally begin within half an hour and last up to six hours. Common side effects include headache, dizziness, and sleepiness. Serious side effects may include addiction, allergic reactions, and seizures. In people with a sulfa allergy certain formulations may cause problems. Safety during pregnancy and breastfeeding is not clear. How it works is not clear. Some of its effects are believed to occur after metabolic conversion into meprobamate, carisoprodol's main active metabolite. Carisoprodol was approved for medical use in the United States in 1959. Its approval in the European Union was withdrawn in 2008. It is available as a generic medication. In 2019, it was the 343rd most commonly prescribed medication in the United States, with more than 800,000 prescriptions. In the United States, it was unscheduled until 2012, when it became a Schedule IV controlled substance.
==== Men's Euro 2028 bid ==== 12 April – The UK–Ireland bid to host the Euro 2028 football tournament was submitted to UEFA, with the Aviva Stadium proposed in Dublin (instead of Croke Park), alongside a redeveloped Casement Park in Belfast. 4 October – Turkey withdrew its bid to host Euro 2028 leaving the only remaining bid unopposed – the joint UK–Ireland one. 10 October – UEFA officially approved the Republic of Ireland, Northern Ireland, England, Scotland and Wales as Euro 2028 co-hosts.
Poly(p-phenylene sulfide) (PPS) is synthesized by the reaction of sodium sulfide with p-dichlorobenzene in a polar solvent such as 1-methyl-2-pyrrolidinone (NMP). It is inherently flame-resistant and stable toward organic and aqueous conditions; however, it is somewhat susceptible to oxidants. Applications of PPS include automotive, microwave oven components, coatings for cookware when blended with fluorocarbon polymers, and protective coatings for valves, pipes, electromotive cells, etc.
A military helicopter ditches in the English Channel near Dorset, killing a member of the Royal Navy. The serviceman is subsequently named as Lt Rhodri Leyshon. 5 September The Competition and Markets Authority (CMA) launches an investigation into the sale of Oasis tickets, following the band's announcement on 27 August and the use of "dynamic pricing". The UK government sets out its plan to abolish hereditary peers in the House of Lords. 6 September 2024 United Kingdom riots: Thomas Birley, 27, is sentenced to nine years in prison for what a judge calls "grotesque" violence at a riot in Rotherham – the longest prison sentence any of those involved has received so far. Russian invasion of Ukraine: A new £162 million package of support for Ukraine is announced by UK Defence Secretary John Healey, which includes an additional 650 short-range missiles. Figures released by the Ministry of Justice indicate the prison population of England and Wales has reached a new high of 88,521. 2024 Summer Paralympics: ParalympicsGB win their 100th medal of the Paris Games, including their 42nd gold, surpassing the 41 golds won at Tokyo 2020. 7 September – The Body Shop is acquired by a consortium led by British cosmetics tycoon Mike Jatania, securing its remaining 113 stores, as well as the positions of its 1,300 shop and office staff. 8 September Great Ormond Street Hospital has launched an urgent review of the cases of more than 700 patients after concerns were raised about one of its former surgeons.
Sources: en.wikipedia.org
AOD9604 is an orally active, lipolytic 16-amino acid peptide fragment of human growth hormone and derivative of the C-terminal domain of human growth hormone (HGH). It consists of HGH residues 176–191, with a tyrosine in place of the phenylalanine at the N-terminal end. Initial human trials showed that it retains the lipolytic properties of human growth hormone without stimulating IGF-1 production. However, later studies failed to demonstrate a sufficient lipolytic effect. Its development was terminated in 2007. Despite its limited efficacy, AOD9604 is still banned in athletes and tested for in competition.
Anders Ericsson of Florida State University did not believe that sufficient evidence existed to suggest that the skills of Price and another documented case, Brad Williams, needed additional explanation: "Our work has pretty much concluded that differences in memory don't seem to be the result of innate differences, but more the kinds of skills that are developed." As the condition has become better known, more people claiming to have hyperthymestic abilities have emerged. In the aftermath of the 2006 Neurocase publication alone, more than 200 people contacted McGaugh; however, only a handful of cases were determined to be actual cases of hyperthymesia. The second verified case was Brad Williams, the third was Rick Baron, and in 2009, Bob Petrella became the fourth person diagnosed with hyperthymestic syndrome. The U.S. television program 60 Minutes featured actress Marilu Henner in 2010 for her superior autobiographical memory ability. Henner claimed to remember almost every day of her life since age 11. The show was initially pitched as a story featuring hyperthymestic violinist Louise Owen, but the reporter Lesley Stahl volunteered her friend Henner as having a similar ability. In 2012, reports emerged of H.K. Derryberry, a blind 20-year-old man who could clearly recall every day of the last nine years of his life. Derryberry had been born at 27 weeks, weighing just over 2 pounds (0.91 kg) and was in neonatal intensive care for 96 days. A brain hemorrhage was the likely cause of cerebral palsy, and his premature birth brought congenital blindness.
2) Order 1993 (S.I. 1993/1821) Occupational Pension Schemes (Preservation of Benefit) Amendment Regulations 1993 (S.I. 1993/1822) Offshore Safety (Repeals and Modifications) Regulations 1993 (S.I. 1993/1823) Export of Goods (Control) (Amendment No. 4) Order 1993 (S.I. 1993/1825) Financial Services (Disclosure of Information) (Designated Authorities) (No. 7) Order 1993 (S.I. 1993/1826) Church of England (Legal Aid) Rules 1993 (S.I. 1993/1840) Diocesan Chancellorship Regulations 1993 (S.I. 1993/1841) Ecclesiastical Judges and Legal Officers (Fees) Order 1993 (S.I. 1993/1842) Legal Officers (Annual Fees) Order 1993 (S.I. 1993/1843) Parochial Fees Order 1993 (S.I. 1993/1844) Local Government Superannuation (Investments) Regulations 1993 (S.I. 1993/1848) Highways (Traffic Calming) Regulations 1993 (S.I. 1993/1849) Education (Mandatory Awards) Regulations 1993 (S.I. 1993/1850) Social Security (Invalid Care Allowance) Amendment (No. 2) Regulations 1993 (S.I. 1993/1851) Assisted Areas Order 1993 (S.I. 1993/1877) Seed Potatoes (Amendment) Regulations 1993 (S.I. 1993/1878) Public Telecommunication System Designation (City of London Telecommunications Ltd) Order 1993 (S.I. 1993/1879) Public Telecommunication System Designation (Ionica L3 Ltd) Order 1993 (S.I. 1993/1880) Companies Act 1989 (Recognised Supervisory Bodies) (Periodical Fees) Regulations 1993 (S.I. 1993/1881) Learning for Work (Scottish Enterprise and Highlands and Islands Enterprise Programmes) Order 1993 (S.I. 1993/1882) Norway Lobsters (Prohibition of Method of Fishing) Order 1993 (S.I.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.